Skip to main content

Research Repository

Advanced Search

Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin.

Reynisson

Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin. Thumbnail


Authors



Abstract

Drugs which inhibit platelet function are commonly used to prevent blood clot formation in patients with Acute Coronary Syndromes (ACS) or those at risk of stroke. The thieno[3,2-c]pyridine class of therapeutic agents, of which clopidogrel is the most commonly used, target the P2Y12 receptor, and are often used in combination with acetylsalicylic acid (ASA). Six thieno[2,3-b]pyridine were assessed for in vitro anti-platelet activity; all derivatives showed effects on both platelet activation and aggregation, and showed synergy with ASA. Some compounds demonstrated greater activity when compared to clopidogrel. These compounds, therefore, represent potential novel P2Y12 inhibitors for improved treatment for patients.

Acceptance Date Nov 4, 2017
Publication Date Jan 1, 2018
Publicly Available Date Mar 28, 2024
Journal European Journal of Medicinal Chemistry
Print ISSN 0223-5234
Publisher Elsevier
Pages 1997 - 2004
DOI https://doi.org/10.1016/j.ejmech.2017.11.014
Keywords Thienopyridine; Platelets; Thrombosis; Clopidogrel; Aspirin
Publisher URL https://www.sciencedirect.com/science/article/pii/S0223523417309078?via%3Dihub

Files




You might also like



Downloadable Citations